Single User License
INR 136040
Site License
INR 272080
Corporate User License
INR 408120

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Obesity-Pipeline Review, H1 2015

Obesity-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Obesity-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Obesity-Pipeline Review, H1 2015', provides an overview of the Obesity's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Obesity, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Obesity and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Obesity

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Obesity and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Obesity products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Obesity pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Obesity

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Obesity pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

Introduction 8

Obesity Overview 9

Therapeutics Development 10

Obesity-Therapeutics under Development by Companies 12

Obesity-Therapeutics under Investigation by Universities/Institutes 21

Obesity-Pipeline Products Glance 25

Obesity-Products under Development by Companies 29

Obesity-Products under Investigation by Universities/Institutes 41

Obesity-Companies Involved in Therapeutics Development 45

Obesity-Therapeutics Assessment 139

Drug Profiles 158

Obesity-Recent Pipeline Updates 407

Obesity-Dormant Projects 458

Obesity-Discontinued Products 474

Obesity-Product Development Milestones 481

Appendix 490

List of Tables

Number of Products under Development for Obesity, H1 2015 33

Number of Products under Development for Obesity-Comparative Analysis, H1 2015 34

Number of Products under Development by Companies, H1 2015 36

Number of Products under Development by Companies, H1 2015 (Contd..1) 37

Number of Products under Development by Companies, H1 2015 (Contd..2) 38

Number of Products under Development by Companies, H1 2015 (Contd..3) 39

Number of Products under Development by Companies, H1 2015 (Contd..4) 40

Number of Products under Development by Companies, H1 2015 (Contd..5) 41

Number of Products under Development by Companies, H1 2015 (Contd..6) 42

Number of Products under Development by Companies, H1 2015 (Contd..7) 43

Number of Products under Investigation by Universities/Institutes, H1 2015 45

Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 46

Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..2) 47

Comparative Analysis by Late Stage Development, H1 2015 48

Comparative Analysis by Clinical Stage Development, H1 2015 49

Comparative Analysis by Early Stage Development, H1 2015 50

Comparative Analysis by Unknown Stage Development, H1 2015 51

Products under Development by Companies, H1 2015 52

Products under Development by Companies, H1 2015 (Contd..1) 53

Products under Development by Companies, H1 2015 (Contd..2) 54

Products under Development by Companies, H1 2015 (Contd..3) 55

Products under Development by Companies, H1 2015 (Contd..4) 56

Products under Development by Companies, H1 2015 (Contd..5) 57

Products under Development by Companies, H1 2015 (Contd..6) 58

Products under Development by Companies, H1 2015 (Contd..7) 59

Products under Development by Companies, H1 2015 (Contd..8) 60

Products under Development by Companies, H1 2015 (Contd..9) 61

Products under Development by Companies, H1 2015 (Contd..10) 62

Products under Development by Companies, H1 2015 (Contd..11) 63

Products under Investigation by Universities/Institutes, H1 2015 64

Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 65

Products under Investigation by Universities/Institutes, H1 2015 (Contd..2) 66

Products under Investigation by Universities/Institutes, H1 2015 (Contd..3) 67

Obesity-Pipeline by Advinus Therapeutics Ltd., H1 2015 68

Obesity-Pipeline by Aegis Therapeutics, LLC, H1 2015 69

Obesity-Pipeline by Aileron Therapeutics, Inc., H1 2015 70

Obesity-Pipeline by Akron Molecules AG, H1 2015 71

Obesity-Pipeline by Alize Pharma SAS, H1 2015 72

Obesity-Pipeline by Ambrx, Inc., H1 2015 73

Obesity-Pipeline by Amgen Inc., H1 2015 74

Obesity-Pipeline by Arena Pharmaceuticals, Inc., H1 2015 75

Obesity-Pipeline by Arrien Pharmaceuticals, LLC, H1 2015 76

Obesity-Pipeline by Arrowhead Research Corporation, H1 2015 77

Obesity-Pipeline by AstraZeneca PLC, H1 2015 78

Obesity-Pipeline by AtheroNova Inc., H1 2015 79

Obesity-Pipeline by Athersys, Inc., H1 2015 80

Obesity-Pipeline by Avaxia Biologics, Inc., H1 2015 81

Obesity-Pipeline by BioRestorative Therapies, Inc., H1 2015 82

Obesity-Pipeline by Braasch Biotech LLC, H1 2015 83

Obesity-Pipeline by Bridge Bioresearch Plc, H1 2015 84

Obesity-Pipeline by Bristol-Myers Squibb Company, H1 2015 85

Obesity-Pipeline by Calzada Limited, H1 2015 86

Obesity-Pipeline by Carmot Therapeutics, Inc., H1 2015 87

Obesity-Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2015 88

Obesity-Pipeline by Chronos Therapeutics Limited, H1 2015 89

Obesity-Pipeline by CrystalGenomics, Inc., H1 2015 90

Obesity-Pipeline by Daiichi Sankyo Company, Limited, H1 2015 91

Obesity-Pipeline by Deltanoid Pharmaceuticals Inc., H1 2015 92

Obesity-Pipeline by Diabetica Limited, H1 2015 93

Obesity-Pipeline by Digna Biotech, S.L., H1 2015 94

Obesity-Pipeline by DiscoveryBiomed, Inc., H1 2015 95

Obesity-Pipeline by Eisai Co., Ltd., H1 2015 96

Obesity-Pipeline by Eli Lilly and Company, H1 2015 97

Obesity-Pipeline by Esperion Therapeutics, Inc., H1 2015 98

Obesity-Pipeline by Euroscreen S.A., H1 2015 99

Obesity-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 100

Obesity-Pipeline by Galapagos NV, H1 2015 101

Obesity-Pipeline by Galenea Corp., H1 2015 102

Obesity-Pipeline by Genfit SA, H1 2015 103

Obesity-Pipeline by GlaxoSmithKline plc, H1 2015 104

Obesity-Pipeline by GTx, Inc., H1 2015 105

Obesity-Pipeline by Handok Inc., H1 2015 106

Obesity-Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2015 107

Obesity-Pipeline by Helsinn Healthcare S.A., H1 2015 108

Obesity-Pipeline by High Point Pharmaceuticals, LLC, H1 2015 109

Obesity-Pipeline by Insusense Therapeutics ApS, H1 2015 110

Obesity-Pipeline by Intarcia Therapeutics, Inc., H1 2015 111

Obesity-Pipeline by Isis Pharmaceuticals, Inc., H1 2015 112

Obesity-Pipeline by Jenrin Discovery, Inc., H1 2015 113

Obesity-Pipeline by Johnson & Johnson, H1 2015 114

Obesity-Pipeline by Kainos Medicine, Inc., H1 2015 115

Obesity-Pipeline by Kissei Pharmaceutical Co., Ltd., H1 2015 116

Obesity-Pipeline by Lead Discovery Center GmbH, H1 2015 117

Obesity-Pipeline by LG Life Sciences, Ltd., H1 2015 118

Obesity-Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2015 119

Obesity-Pipeline by Molecular Design International, Inc., H1 2015 120

Obesity-Pipeline by Neothetics, Inc. , H1 2015 121

Obesity-Pipeline by NGM Biopharmaceuticals, Inc., H1 2015 122

Obesity-Pipeline by nLife Therapeutics, S.L., H1 2015 123

Obesity-Pipeline by Nordic Bioscience a/s, H1 2015 124

Obesity-Pipeline by Novo Nordisk A/S, H1 2015 125

Obesity-Pipeline by ObeTherapy Biotechnology, H1 2015 126

Obesity-Pipeline by Omeros Corporation, H1 2015 127

Obesity-Pipeline by OPKO Health, Inc., H1 2015 128

Obesity-Pipeline by Orbis Biosciences, Inc., H1 2015 129

Obesity-Pipeline by Orchid Chemicals & Pharmaceuticals Ltd, H1 2015 130

Obesity-Pipeline by Orexigen Therapeutics, Inc., H1 2015 131

Obesity-Pipeline by P2D Bioscience, H1 2015 132

Obesity-Pipeline by Pfizer Inc., H1 2015 133

Obesity-Pipeline by PharmaIN Corporation, H1 2015 134

Obesity-Pipeline by Piramal Enterprises Limited, H1 2015 135

Obesity-Pipeline by Plexxikon Inc., H1 2015 136

Obesity-Pipeline by Prometheon Pharma, LLC, H1 2015 137

Obesity-Pipeline by Regulus Therapeutics Inc., H1 2015 138

Obesity-Pipeline by Reviva Pharmaceuticals Inc., H1 2015 139

Obesity-Pipeline by Rhythm Pharmaceuticals, H1 2015 140

Obesity-Pipeline by Saniona AB, H1 2015 141

Obesity-Pipeline by Sanofi, H1 2015 142

Obesity-Pipeline by Shanghai Pharmaceutical Co., Ltd., H1 2015 143

Obesity-Pipeline by Shionogi & Co., Ltd., H1 2015 144

Obesity-Pipeline by Sirona Biochem Corp, H1 2015 145

Obesity-Pipeline by Sorrento Therapeutics, Inc., H1 2015 146

Obesity-Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2015 147

Obesity-Pipeline by Suven Life Sciences Ltd., H1 2015 148

Obesity-Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 149

Obesity-Pipeline by Transition Therapeutics Inc., H1 2015 150

Obesity-Pipeline by Upsher-Smith Laboratories, Inc., H1 2015 151

Obesity-Pipeline by Versartis, Inc., H1 2015 152

Obesity-Pipeline by Verva Pharmaceuticals Limited, H1 2015 153

Obesity-Pipeline by Vicore Pharma AB, H1 2015 154

Obesity-Pipeline by WhanIn Pharmaceutical Co., Ltd., H1 2015 155

Obesity-Pipeline by X-BODY BioSciences, Inc., H1 2015 156

Obesity-Pipeline by Xenetic Biosciences plc, H1 2015 157

Obesity-Pipeline by XL-protein GmbH, H1 2015 158

Obesity-Pipeline by Zafgen Inc., H1 2015 159

Obesity-Pipeline by Zealand Pharma A/S, H1 2015 160

Obesity-Pipeline by Zydus Cadila Healthcare Limited, H1 2015 161

Assessment by Monotherapy Products, H1 2015 162

Assessment by Combination Products, H1 2015 163

Number of Products by Stage and Target, H1 2015 165

Number of Products by Stage and Mechanism of Action, H1 2015 172

Number of Products by Stage and Route of Administration, H1 2015 178

Number of Products by Stage and Molecule Type, H1 2015 180

Obesity Therapeutics-Recent Pipeline Updates, H1 2015 430

Obesity-Dormant Projects, H1 2015 481

Obesity-Dormant Projects (Contd..1), H1 2015 482

Obesity-Dormant Projects (Contd..2), H1 2015 483

Obesity-Dormant Projects (Contd..3), H1 2015 484

Obesity-Dormant Projects (Contd..4), H1 2015 485

Obesity-Dormant Projects (Contd..5), H1 2015 486

Obesity-Dormant Projects (Contd..6), H1 2015 487

Obesity-Dormant Projects (Contd..7), H1 2015 488

Obesity-Dormant Projects (Contd..8), H1 2015 489

Obesity-Dormant Projects (Contd..9), H1 2015 490

Obesity-Dormant Projects (Contd..10), H1 2015 491

Obesity-Dormant Projects (Contd..11), H1 2015 492

Obesity-Dormant Projects (Contd..12), H1 2015 493

Obesity-Dormant Projects (Contd..13), H1 2015 494

Obesity-Dormant Projects (Contd..14), H1 2015 495

Obesity-Dormant Projects (Contd..15), H1 2015 496

Obesity-Discontinued Products, H1 2015 497

Obesity-Discontinued Products (Contd..1), H1 2015 498

Obesity-Discontinued Products (Contd..2), H1 2015 499

Obesity-Discontinued Products (Contd..3), H1 2015 500

Obesity-Discontinued Products (Contd..4), H1 2015 501

Obesity-Discontinued Products (Contd..5), H1 2015 502

Obesity-Discontinued Products (Contd..6), H1 2015 503

List of Figures

Number of Products under Development for Obesity, H1 2015 33

Number of Products under Development for Obesity-Comparative Analysis, H1 2015 34

Number of Products under Development by Companies, H1 2015 35

Number of Products under Investigation by Universities/Institutes, H1 2015 44

Comparative Analysis by Late Stage Development, H1 2015 48

Comparative Analysis by Clinical Stage Development, H1 2015 49

Comparative Analysis by Early Stage Products, H1 2015 50

Assessment by Monotherapy Products, H1 2015 162

Assessment by Combination Products, H1 2015 163

Number of Products by Top 10 Targets, H1 2015 164

Number of Products by Stage and Top 10 Targets, H1 2015 164

Number of Products by Top 10 Mechanism of Actions, H1 2015 171

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 171

Number of Products by Top 10 Routes of Administration, H1 2015 177

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 177

Number of Products by Top 10 Molecule Types, H1 2015 179

Number of Products by Stage and Top 10 Molecule Types, H1 2015 179

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Advinus Therapeutics Ltd.

Aegis Therapeutics, LLC

Aileron Therapeutics, Inc.

Akron Molecules AG

Alize Pharma SAS

Ambrx, Inc.

Amgen Inc.

Arena Pharmaceuticals, Inc.

Arrien Pharmaceuticals, LLC

Arrowhead Research Corporation

AstraZeneca PLC

AtheroNova Inc.

Athersys, Inc.

Avaxia Biologics, Inc.

BioRestorative Therapies, Inc.

Braasch Biotech LLC

Bridge Bioresearch Plc

Bristol-Myers Squibb Company

Calzada Limited

Carmot Therapeutics, Inc.

Chong Kun Dang Pharmaceutical Corp.

Chronos Therapeutics Limited

CrystalGenomics, Inc.

Daiichi Sankyo Company, Limited

Deltanoid Pharmaceuticals Inc.

Diabetica Limited

Digna Biotech, S.L.

DiscoveryBiomed, Inc.

Eisai Co., Ltd.

Eli Lilly and Company

Esperion Therapeutics, Inc.

Euroscreen S.A.

F. Hoffmann-La Roche Ltd.

Galapagos NV

Galenea Corp.

Genfit SA

GlaxoSmithKline plc

GTx, Inc.

Handok Inc.

Hanmi Pharmaceuticals, Co. Ltd.

Helsinn Healthcare S.A.

High Point Pharmaceuticals, LLC

Insusense Therapeutics ApS

Intarcia Therapeutics, Inc.

Isis Pharmaceuticals, Inc.

Jenrin Discovery, Inc.

Johnson & Johnson

Kainos Medicine, Inc.

Kissei Pharmaceutical Co., Ltd.

Lead Discovery Center GmbH

LG Life Sciences, Ltd.

Mitsubishi Tanabe Pharma Corporation

Molecular Design International, Inc.

Neothetics, Inc.

NGM Biopharmaceuticals, Inc.

nLife Therapeutics, S.L.

Nordic Bioscience a/s

Novo Nordisk A/S

ObeTherapy Biotechnology

Omeros Corporation

OPKO Health, Inc.

Orbis Biosciences, Inc.

Orchid Chemicals & Pharmaceuticals Ltd

Orexigen Therapeutics, Inc.

P2D Bioscience

Pfizer Inc.

PharmaIN Corporation

Piramal Enterprises Limited

Plexxikon Inc.

Prometheon Pharma, LLC

Regulus Therapeutics Inc.

Reviva Pharmaceuticals Inc.

Rhythm Pharmaceuticals

Saniona AB

Sanofi

Shanghai Pharmaceutical Co., Ltd.

Shionogi & Co., Ltd.

Sirona Biochem Corp

Sorrento Therapeutics, Inc.

Sumitomo Dainippon Pharma Co., Ltd.

Suven Life Sciences Ltd.

Takeda Pharmaceutical Company Limited

Transition Therapeutics Inc.

Upsher-Smith Laboratories, Inc.

Versartis, Inc.

Verva Pharmaceuticals Limited

Vicore Pharma AB

WhanIn Pharmaceutical Co., Ltd.

X-BODY BioSciences, Inc.

Xenetic Biosciences plc

XL-protein GmbH

Zafgen Inc.

Zealand Pharma A/S

Zydus Cadila Healthcare Limited

Obesity Therapeutic Products under Development, Key Players in Obesity Therapeutics, Obesity Pipeline Overview, Obesity Pipeline, Obesity Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com